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Effect of in-hydroxycholecalciferol on glomerular filtration rate in
children with moderate renal failure. F. U. Eke and /'4. H. Winterborn.
East Birmingham Hospital, Birmingham, England. During a study of
lo-hydroxycholecalciferol (la-HCC) for renal osteodystrophy in chil-
dren with moderate renal failure, serial measurements of 51Cr-EDTA
clearance were made to assess its effect on renal function. Sixteen
children with moderate impairment of renal function (GFR 20 to 50 ml!
min/l.73 m2) were entered into a double blind trial of la-HCC 10 ng
1.4 nglkglday (group A) versus calciferol 640 ng 130 ng/kg/day (group
B) for 1 year. Investigations included bone X-rays and serial measure-
ments of height, blood biochemistry, and parathyroid hormone (PTH).
51Cr-EDTA clearances and bone biopsies were performed at the
beginning and end of the study.
51Cr-EDTA clearance (ml/min/l.73 m2)
Duration of
treatment 0 6 months 12 months
Group A 33.0 13.6 44.8 16.5 35.6 15.4
Group B 30.9 12.3 29.1 7.0 30.3 8.5
The rise in GFR in group A was significant at 6 months (P < 0.02) but
not at 12 months (P = 0.56). There was no significant change in GFR in
group B. Paired t tests showed no significant differences between the
two groups. There were no episodes of hypercalcemia during the study.
Serum phosphate rose in group A at 3 months (P < 0.02). PTH levels
fell significantly (P = 0.01) after 6 months in group A but did not change
in group B. Several authors have implicated la-HCC as an important
cause of deterioration in renal function in patients with advanced renal
failure. This study shows that la-HCC can be used in children with
moderate renal failure without jeopardizing renal function. A dose of 10
ng 1.4 ng/kg!day is effective in suppressing PTH without causing a fall
in GFR.
increased plastic-adherent mononuclear suppressor cell activity in
patients with minimal change nephropathy. D. Taube, Z. Brown, and D.
G. Williams. Renal Unit, Guy's Hospital, London, England. Lympho-
cytes from patients with minimal change nephropathy (MCN) both in
relapse and remission respond poorly to mitogens. As macrophages
play an important role in the regulation of lymphocyte responses to
mitogens and also produce potent inhibitors of lymphocyte function
such as a 2 macroglobulin, we have assessed the role of this type of cell
in the response of lymphocytes to the T-cell mitogen concanavalin A
(CON A) in patients with MCN. We studied 10 patients with MCN in
relapse and 27 patients with MCN in long-term remission. Thirty-five
normal individuals and II patients with membranous nephropathy
served as controls. Mononuclear cells were removed from peripheral
blood lymphocyte cultures by adherence to fetal calf serum-coated
plastic petri dishes. These plastic-adherent mononuclear cells (PAM5)
were esterase positive and phagocytosed iron filings, thus exhibiting
some of the properties of macrophages. Lymphocyte responsiveness to
CON A in the whole cultures was impaired in the patients with MCN in
relapse (P < 0.01), MCN in remission (P < 0.01), and also in the
patients with membranous nephropathy (P < 0.05) when compared with
the normal subjects. Removal of these PAMs from the lymphocyte
cultures resulted in a significantly increased lymphocyte response to
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CON A in both groups of patients with MCN and in the patients with
membranous nephropathy. This increase in CON A responsiveness was
significantly greater than in the normal subjects (P < 0.01) for each
group. Re-addition of the PAMs to the depleted cultures restored the
lymphocyte response to CON A to a level similar to that of the whole
cultures. Six patients with MCN in relapse were studied sequentially
before steroid therapy and then in early remission after cessation of
steroids. Four patients showed markedly decreased PAM suppressor
activity in remission, and two patients, who subsequently relapsed,
exhibited increased PAM suppressor activity during relapse. This
finding was further confirmed by the observation that in patients with
MCN in long-term remission PAM suppressor activity was significantly
increased (P < 0.05) in the 11 patients who continued to relapse after
presentation when compared with 16 patients who had no further
relapses. Our data indicate that PAMs play a suppressor role in the
response to mitogens of patients with MCN in relapse and remission.
This finding is not specific for MCN as similar abnormalities occur in
membranous nephropathy. Although the significance of our findings is
not clear, increased PAM suppressor activity by reducing lymphocyte
responsiveness to antigens as well as to mitogens may contribute to the
increased incidence of infection associated with the nephrotic
syndrome.
The prognosis after immunosuppression of patients with crescentic
nephritis requiring dialysis. C. R. K. Hind, C. M. Lockwood, D. J.
Evans, and A. J. Rees. Department of Medicine, Royal Postgraduate
Medical School, Hammersmith Hospital, London, England. Crescentic
nephritis with renal failure severe enough to necessitate dialysis has a
poor prognosis and a variable response to immunosuppression with its
attendant dangers. We have studied prospectively 48 such patients to
see which factors influence recovery. At presentation the patients
needed dialysis and had severe nephritis with an average of 77%
glomeruli surrounded by crescents. Twenty-one had antibodies to
glomerular basement membrane (GBM), 17 Wegener's granulomatosis,
7 polyarteritis, and 3 had isolated nephritis. Forty-five patients were
treated with immunosuppression by prednisolone; cyclophosphamide
was used in 42 patients, and azathioprine in 21. Forty-one had plasma
exchange. There was a striking difference in the response to treatment
depending on the diagnosis; one of 21 patients with anti-GBM antibod-
ies recovered renal function and 11 have died. In contrast 17 of 27(63%)
without anti-GBM antibodies recovered, after up to 28 days' dialysis.
Furthermore, four patients who recovered had been dialysed for over
10 days before starting immunosuppressive treatment. Six of these
patients have died, three of infection, two of uncontrolled vasculitis,
and one of a stroke. One patient subsequently developed end-stage
renal failure. Nine are well with stable plasma creatinine concentrations
between 80 to 400 smoles/liter, up to 63 months later. This experience
emphasizes the importance of defining the immunopathogenic mecha-
nisms of severe crescentic nephritis when predicting prognosis for
recovery of renal function. Patients with anti-GBM antibodies do not
respond if treatment is started after dialysis. In contrast, those patients
with GBM antibodies usually do respond to aggressive immunosuppres-
sive treatment.
Urinary N-acetylglucosaminidase activity in the management of steroid-
responsive nephrotic syndrome in childhood. J. T. Brocklebank and S. R.
Meadow. St. James's University Hospital, Leeds, England. The man-
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agement of steroid-responsive nephrotic syndrome in childhood is
difficult because of the frequency of relapses after initial steroid
treatment. The routine method of detecting a relapse is by examination
for proteinuria by the Albustix test, but it has not proven to be
sufficiently specific and treatment is often delayed until significant
proteinuria has been present for 10 days. A simple and specific method
of detecting relapses early would help in the management of nephrotic
children. This study was designed to compare the routine measurement
of urinary N-acetylglucosaminidase activity (NAG) with the Albustix
test in the outpatient management of steroid-responsive nephrotic
syndrome in childhood. Random urine samples were obtained from 36
children with steroid-responsive nephrotic syndrome during their out-
patient attendances and examined for NAG, creatinine, and protein
(Albustix). The results were compared and related to the activity of the
nephrotic syndrome. Urinary NAG averaged 2.7 mmole/ml/hr/temole
creatinine in 71 normal, but 6.7 in the 36 nephrotic children. A
remarkably high urinary NAG was found in 13 children who were
treated for relapses. Their urinary NAG activity averaged 34.5 mmoles/
ml/hr/lsmole creatinine compared with 2.9 in those who were in
remission. The activity increased with greater degrees at proteinuria,
averaging 4.9 and 32.1 mmole/ml/hr/tmole creatinine, respectively, in
the presence of negative and 4+ Albustix tests. Measurement of NAG
proved helpful in detecting relapses in children with minor degrees of
proteinuria. Six children with negative Albustix tests were treated for
relapse within 28 days. Their mean urinary NAG was 22.3 mmoles/ml/
hr/imole creatinine. In contrast, the mean urinary NAG in those with
negative Albustix tests and in remission was 2.4. The mean NAG
activities during relapses and with 1+, 2+, and 3+ Albustix tests were
52.7, 49.8, and 27.9 mmole/ml/hr/mole creatinine, respectively. These
studies show that the urinary NAG activity of children with steroid-
sensitive nephrotic syndrome in remission is similar to that of control
subjects. It increases significantly during a relapse. It is suggested that
urinary NAG measurement may be a useful method of detecting
relapses in steroid-sensitive nephrotic syndrome before significant
proteinuria occurs.
Treatment with Cyclosporin A inhibits acute serum sickness nephritis
in rabbits. G. H. Neild, K. Ivory, and D. G. Williams, Renal Unit,
Guy's Hospital, London, England. Glomerular proliferation in acute
serum sickness (ASS) nephritis in rabbits is predominantly the result of
influx of monocytes into the glomerulus, and, recently, it has been
shown that depletion of circulating monocytes by a specific antimacro-
phage antiserum inhibits both the glomerular proliferation and the
proteinuria associated with the glomerular injury. To examine the
hypothesis that part of the injury in ASS might be T-cell mediated, we
treated rabbits with ASS with the immunosuppressive agent Cyclo-
sporin A (Cy A). In our model of ASS in NSW rabbits, a single large
injection of bovine serum albumin (BSA) (250 mg/kg) was given
together with a small dose of Escherichia coli endotoxin (5 pg/kg). BSA
was eliminated after a mean of 8.6 0.16 days (mean 5EM) (N 23).
Histological examination of kidney obtained postmortem on day 12
showed that 87% of rabbits had glomerular proliferation; proteinuria in
excess of normal (>150 mg/day) occurred for 2 or more consecutive
days in 84% of rabbits. Doses of Cy A known to suppress allograft
rejection in rabbits caused profound reduction in proteinuria and
inhibition of glomerular proliferation in this model of ASS. Cy A (15 mg/
kg) given to 12 rabbits from days ——2 to +8 and 25 mg/kg Cy A given to
five rabbits from days —2 to +3 reduced proteinuria (P < 0.0001, P =
0.0003, respectively) and reduced glomerular proliferation (P < 0.0001,
P = 0.009, respectively; Fisher exact probability test). In a further
experiment, nine rabbits were first treated with 25 mg/kg/day of Cy A 5
days after the induction of ASS, that is, after T-cell sensitization by
BSA. Again, both proteinuria (P = 0.00011; Fisher exact probability
test) and glomerular proliferation (P = 0.0005) were inhibited. When
compared with controls receiving only injections of the solvent vehicle,
there were no differences in the following: time to elimination of BSA,
amount or size of circulating immune complexes, fall in C3 at immune
elimination, or deposition of immune reactants in the glomeruli. Cyclo-
sporin A has been shown to suppress tissue injury in several experimen-
tal models of T-cell mediated disease, even when first given several
days after induction of the disease. Cyclosporin A has not been shown
to have any effect on macrophages or monocyte-mediated injury. The
inhibitory effect of Cy A on the development of the renal injury in ASS
could thus be explained if this injury were mediated by T-cells.
Renal transplantation in very young children. R. S. Trompeter, M.
Bewick, Al. Bosque, G. B. Haycock and C. Chantler. Guy's Hospital,
London, England. Since September 1979, 12 cadaver and three live
donor transplants have been undertaken in 14 recipients (11 male, 3
female) aged less than 5 years of whom six were less than 3 years. The
mean weight of the recipients was 11.5 kg (range 8 to IS); six weighed
less than 10 kg at the time of operation. The mean age of the cadaveric
donors was 13.5 years (range 1.2 to 45). At the time of transplantation
bilateral nephrectomy was performed in five children and unilateral
nephrectomy in three. Bilateral nephrectomy was performed pre-
transplantation in three children and unilateral nephrectomy post-
transplantation in one. Seven patients were transplanted from peritone-
al, two from hemodialysis, and five without prior dialysis. Furosemide
and dopamine were given routinely intra-operatively in addition to
intensive circulatory support intra- and post-operatively, controlled by
continuous monitoring of central venous pressure, arterial pressure,
central peripheral temperature gap and weight. After a mean follow-up
period of 12 months (range 1 to 31), three patients have died and one
graft has failed. The mean plasma creatinine in the survivors is 51
moles/liter (range 29 to 97); estimated GFR 81 ml/min/l.73 m2 (range
49 to 106). Three grafts were lost to chronic vascular rejection principal-
ly affecting large blood vessels. The fourth failed following the unex-
pected finding of a thrombosed inferior vena cava at the time of
operation; none were lost due to arterial thrombosis or other surgical
problems. Seven children observed for more than 8 months (range 8 to
31) have continued to show satisfactory linear growth while on an
alternate day steroid regimen. These results are comparable with those
obtained in adults and older children, and we consider that age, at least
outside the first six months of age, and/or small size should not be
regarded as contraindications for renal transplantation. Careful control
of the circulation to avoid hypo- or hypervolemia and the maintenance
of a high rate of urine flow in the post-operative period appear to have
prevented the high rate of graft loss due to thrombosis or primary non-
function previously reported with cadaver donor grafts in young
children.
B lymphocyte antibodies in successful renal transplantation and suc-
cessful pregnancy. D. A. Power, A. M. MacLeod, R. J. Mason, K. N.
Stewart, U. R. D. Catto, and N. Edward. Department of Medicine,
Aberdeen Royal Infirmary, Foresierhill, Aberdeen, Scotland. The
nature of the beneficial transfusion effect in renal transplantation
remains controversial. However, it does appear that transfusion engen-
ders a protective mechanism and that the effect is not simply one of
patient sensitization and exclusion. We have demonstrated that renal
allograft survival is improved when non-cytotoxic Fe receptor blocking
antibodies directed against donor B lymphocytes are present in recipi-
ent sera before transplantation. Using the erythrocyte antibody inhibi-
tion assay (EAT) with panels of specific donor, normal and leukemic B
lymphocytes as targets, we found (1) 13 out of 15 grafts with but only II
out of 25 grafts without antidonor EAI survived I year (P <0.02); (2) 18
out of 23 grafts with but only 12 out of 27 without EAI against the
normal B cell panel survived 1 year (P < 0.05), and (3) 21 out of 26
grafts with but only 9 out of 24 grafts without anti-CLL EAI survived I
year (P < 0.005). Panel studies suggested that the target antigens were
not HLA-A, B or DR. We now present evidence that such antibodies
are generated by blood transfusion, since (1) 11 out of II patients with
antidonor EAT had received >5 U of blood and (2) 7 out of 12
prospective transplant recipients developed EAT against the leukemic B
cell panel during the course of transfusion. To extend this work we
studied a group of women who had a spontaneous first trimester
abortion and compared them with women of similar gestation and
parity. EAT against paternal B lymphocytes was detected in 7 out of I 1
normal pregnant women but in 0 out of 9 women who aborted. The
mean level of EAT for the normal pregnant women was 33.5 12.5%
and 5.4 6.8% for the women who aborted (P <0.001). Family studies
demonstrated linkage of the antigens detected to the HLA gene
complex. These studies suggest that (1) an alloantigenic system coded
for by MHC-linked genes has been detected; (2) the antigens are not
included within the current serologically-defined antigen systems HLA-
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A, B or DR and (3) that disparity at this antigenic site in some way
abrogates the rejection reaction.
Treatment of secondary hyperparathyroidism by phosphate restriction
in children with chronic renal failure. R. Mak, C. Turner, H. Powell, G.
Haycock, and C. Chantler. Evelina Department of Paediatrics, Guy's
Hospital, London, England. The role of phosphate retention in the
development of secondary hyperparathyroidism (2° HPD) in chronic
renal failure (CRF) is well established. Eleven children with CRF (GFR
5 to 30 ml/min/l .73 m), nine with and two without 2° HPD were treated
with a reduced phosphate diet and with phosphate binders in doses
calculated to reduce absorption in proportion to the level of renal
function over 6 months. Prospective dietary assessment and urine
collection over 3 days were performed every month to assess phosphate
balance. The aim of treatment was to suppress 2° HPD and to raise
tubular reabsorption of phosphate (TRP) to near normal values (80 to
95%) with avoidance of hypophosphatemia and the least amount of
dietary restriction. The mean pre-treatment level of parathyroid hor-
mone (PTH) was 1350 ng/liter (normal range below 450) in the nine
children with 2° HPD; the mean TRP for the group before treatment was
45%. At the end of 6 months of treatment PTH levels were normal in all
patients (mean 200) and TRP rose to a mean of 68%. Plasma creatinine
and calcium concentrations were unchanged during the study period;
plasma phosphate declined from 1.72 0.28 mmoles/liter to 1.23 0.23
mmoles/liter (P < 0.01). Protein intake was not significantly lower
during the reduced phosphate diet. Restricting phosphate absorption in
proportion to the level of renal function without lowering protein intake
resulted in suppression of 2° HPD.
Influence of aluminum on calcium and parathyroid hormone metabo.
lism in dialyzed patients. J. B. Cannata, J. D. Briggs, J. Jay, B. J. R.
Junor, G. Beastall, and G. S. Fell. Renal Unit, Western Infirmary and
University Department of Pathological Biochemistry, Royal Infirmary,
Glasgow, Scotland. Knowledge of parathyroid hormone (PTH) and
aluminum (Al) metabolism has increased in recent years but their
interre1ationship remains unclear. This study has two components.
Firstly, we measured serum Al, calcium (Ca), phosphorus (P), and PTH
on a single occasion in 86 patients who had been receiving hemodialysis
for more than 6 months. Secondly, we carried out the same measure-
ments serially in 20 patients receiving continuous ambulatory peritoneal
dialysis (CAPD) who were accidentally exposed to a high Al level in the
dialysate for 1 month. The hemodialyzed patients were separated into
three groups according to their serum PTH levels. The table shows that
both the serum Al and serum Ca were higher in group 1 (normal PTH)
than in group 3 (high PTH). The differences were significant for both Al
(P < 0.003) and Ca (P < 0.0 125).
both for Al (P < 0.0025) and Ca (P < 0.0025). There were no changes in
Ca or vitamin D therapy either during the period of study or the
preceding 3 months. Our finding that the serum Ca was higher in the
group of hemodialyzed patients with higher serum Al and lower PTH
levels suggests that Al suppresses PTH through an elevation of the
serum Ca. The occurrence of a rise in serum Ca during a period of Al
toxicity in the CAPD-treated patients adds strong support to this
hypothesis.
A prospective randomized trial of operative versus non.operative
management of severe vesico-ureteric reflux: Two-year follow.up of 96
children. R. Astley, R. C. Clark, J. J. Corkery, P. Gornall, G. E. Knox,
K. J. Shah, C. M. Taylor, R. H. R. White, and M. H. Winterborn. The
Children's Hospital and Department of Social Medicine, Birmingham
University, Birmingham, England. Since 1975, children found to have
severe primary vesico-ureteric reflux (VUR) have been allocated ran-
domly to operative or non-operative management in three age strata:
<1 year, 1 to 5 years, and a'6 years. Continuous chemoprophylaxis was
given to both treatment groups. The following observations were made
at entry and at 2 and 5 years: intravenous urogram, cystourethrogram,
51Cr EDTA clearance, plasma creatinine, and overnight urine osmolali-
ty. Growth and blood pressure were monitored tn-monthly and urine
checked for infection (UTI). This report concerns 109 children who
have completed 2 years' follow-up; 13 of these were withdrawn for
failure to comply with protocol or inadequate data, leaving 96 children
in whom 135 allocated ureters and kidneys were studied. Radiological
assessment was made without knowledge of the mode of treatment.
Renal length was related to the intervertebral distance L1 to L1 and
expressed as a SD score. Parenchymal scarring was evaluated as either
new scar formation or progression of that observed at entry. Observa-
tions at entry and at 2 years were compared statistically using either x2
test (Yates corrected) or Student's t test. At 2 years there were no
significant differences in renal growth and scarring, or in renal excre-
tory function in the operative and non-operative groups. There was an
equal incidence of breakthrough UTI in each treatment group, and in
those kidneys exposed to UTI there was no significant difference in
renal growth, scar progression or formation. Children aged >6 years
who were treated operatively had a significantly higher mean urine
osmolality at 2 years (P < 0.05). We are currently investigating the
nature of this difference. Ureteric reimplantation was technically suc-
cessful in 67 out of 69 instances (97%); no ureteric obstruction or other
serious complication arose as a result of surgery. Of the 65 ureters
managed non-operatively 36 (55%) showed persistent severe reflux. In
the 2 years' observation period no clinical advantage has emerged as a
result of either form of management. However, the potential risks of
longstanding, unresolved VUR require further evaluation, and this
study includes further assessment 5 years after entry.
Group I
<600
(normal PTH group)
Group 2
600 to 900
(borderline PTH group)
Group 3
>900
(high PTH group)
In CAPD-treated patients, after using the high Al dialysate for I month,
the mean serum Al rose from 1.85 1.65 to 7.11 4.09 rmoles/liter (P
< 0.0005). Over the same period the mean serum Ca rose from 2.27
0.24 to 2.44 0.21 mmoles/liter (P < 0.0025). The mean serum PTH fell
from 744 599 to 580 580 ng/liter but this difference was not
significant. After a further 2 months using Al-free dialysate, the mean
serum Al fell to 1.92 1.38 iimoles/fiter and the mean serum Ca to 2.22
0.18 mmoles/liter. These levels were significantly less than the peaks
An inhibitor of prostacyclin production in the plasma of some children
with the hemolytic uremic syndrome and thrombotic thrombocytopenic
purpura. M. Levin, K. B. Elkon, A. M. Buckle, T. J. Nokes, M. J.
Dillon, R. M. Hardisty, and T. M. Barratt. Departments of Nephrology
and Haematology, Institute of Child Health, London, England. Re-
duced prostacyclin (PGI2) production has been demonstrated previous-
ly when endothelial tissue is incubated with plasma from patients with
hemolytic uremic syndrome (HUS). This abnormality has been ascribed
to deficiency of a factor present in normal plasma necessary for PGI2
production. We have studied PGI2 production by rat aortic rings
incubated with plasma from nine children with HUS Efour with the
epidemic variety (EpHUS) and five with the sporadic variety (SpHUS)]
and two children with thrombotic thrombocytopenic purpura (TTP).
PGI2 production, measured by inhibition of platelet aggregation, was
diminished when the rings were incubated with plasma from four of the
five children with SpHUS and from one of the children with TTP but
was normal with plasma from children with EpHUS and other renal
diseases. Fractionation and stability studies showed that the reduced
PGI2 production was due to an inhibitor which is unstable and is
extractable into polar lipid solvents. These results suggest that different
pathogenic mechanisms may be involved in SpHUS and EpHUS, and
that the PGI2 reduction observed in SpHUS is due to an inhibitor of
PGI2 production rather than a deficiency of plasma-stimulating factors
as has been suggested previously.
PTH
nglliter
Number
of
patients
Serum Ca Serum Al
mmoles/liter p..moles/liter
29 2.43 0.23 4.85 3.70
10 2.40 0.14 3.48 1.74
47 2.32 0.24 2.84 1.55
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In vitro studies of glomerular disease. M. Davies, M. J. Harher and G.
A. Co/es. Department of Renal Medicine, Welsh National School of
Medicine, K.R. CF. institute of Renal Disease, Cardiff Royal infirma-
ry, CardIf Wales. We have shown previously that pure polymorphonu-
clear leucocyte proteinases can degrade glomerular basement mem-
brane-(GBM). We also have provided evidence that these enzymes are
pathogenic in some cases of human glomerulonephritis. However, the
exact sequence of events in the glomerulus is still unclear. To study the
disease process further we have developed an in vitro model of
glomerular disease. Aliquots of human GBM were pre-incubated with
various proteins, washed and then exposed to human polymorphonu-
clear leucocytes (PMNs). Activation of PMNs was detected by measur-
ing the amount of luminol-enhanced chemiluminescence. GBM alone
evoked no response and pre-incubation with normal human or rabbit
serum caused little or no activation. Following treatment with rabbit
anti-human GBM there was marked PMN activation. This response was
enhanced by an additional pre-incubation phase with fresh normal
human serum (NHS) but not by heat inactivated serum. Goodpasture
serum also caused chemiluminescence but to a lesser degree, probably
owing to the lower titre of antibody present. We conclude that anti-
GBM disease may evoke a PMN response through both Fe and
complement receptors. Further studies using this system showed that a
chemiluminescent response was followed by selective release of Tyso-
sonial enzymes including neutral proteinases. When GBM was incubat-
ed with PMNs in the presence of fresh NHS, some chemiluminescence
occurred. Since there was no response to heat-inactivated serum, this
suggests a complement-mediated effect. This was substantiated by two-
dimensional immunoelectrophoresis using anti-human C3. If GBM was
incubated with anti-human GBM and then fresh NHS was added, the
supernatant showed marked activation of C3. The addition of fresh
NHS alone to GBM also caused the C3 change but to a lesser degree.
Further experiments suggest that GBM treated with PMN neutral
proteinases activates complement to a greater degree than when only
exposed to NHS.
